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Abstract
 
Suppressor of cytokine signaling (SOCS)3 has been characterized as a negative feedback regula-
tor in cytokine-mediated Janus kinase signal transducer and activator of transcription signaling.
However, this study shows that T cells from transgenic mice expressing SOCS3 exhibit a sig-
nificant reduction in interleukin (IL)-2 production induced by T cell receptor cross-linking
when T cells are costimulated with CD28. Decreased protein expression in SOCS3
 
 
 
/
 
  
 
mice
enhanced CD28-mediated IL-2 production, clearly indicating the correlation between ex-
pression level of SOCS3 and IL-2 production ability. The SOCS3 protein interacted with
phosphorylated CD28 through its SH2 domain but not the kinase inhibitory region. In addi-
tion, a point mutation in the SOCS3 SH2 domain attenuated the inhibition of CD28 function
in IL-2 promoter activation. Committed T helper (Th)2 cells exclusively expressed SOCS3
and production of Th2 cytokines, such as IL-4 and IL-5, was much less dependent on CD28
costimulation compared with interferon 
 
  
 
and IL-2 production in Th1 cells. Consistent with
this notion, the expression level of SOCS3 in early T cell activation influenced the ability of
IL-2 production induced by CD28 costimulation. Therefore, the SOCS3 may play an alterna-
tive role in prohibiting excessive progression of CD28-mediated IL-2 production.
Key words: CD28 • costimulation • IL-2 production • SOCS • T cell activation
 
Introduction
 
T cell activation is triggered by the interaction between
peptide-bound MHC molecules on APCs and TCR on T
cells. An additional receptor–ligand interaction results in
the full activation of T cells by providing costimulatory sig-
nals. One prominent T cell costimulatory receptor that has
been studied extensively is the CD28 molecule (1, 2).
CD28 is expressed on the majority of mature T cells and
binds to B7-1 (CD80) and B7-2 (CD86) that are either in-
duced or constitutively expressed on APCs. The CD28
binding to those ligands results in T cell costimulation
whereas the binding of cytotoxic T lymphocyte–associated
antigen 4, a structurally homologous receptor to CD28, re-
sults in the inhibition of T cell activation (3–5). CD28 co-
stimulation plays an essential role on IL-2 production in
primary T cell activation, driving subsequent cell cycle
progression and cell commitment. In its absence T cells be-
come anergic (6).
The cytokine signaling is known to be regulated by a
negative feedback regulator called suppressor of cytokine
signaling (SOCS),
 
*
 
 the cytokine-inducible SH2-containing
protein (CIS), and signal transducer and activator of tran-
scription (STAT)-induced STAT inhibitors family (7–9).
Members of the SOCS family have been identified due to
their marked homology on the SH2 domain and a unique
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Abbreviations used in this paper:
 
 CIS, cytokine-inducible SH2-containing
protein; ERK, extracellular signal–regulated kinase; Grb2, growth factor
receptor–bound protein; GST, glutathione 
 
S
 
-transferase; JAK, Janus ki-
nase; KIR, kinase inhibitory region; NF, nuclear factor; PI3-K, phos-
phatidylinositol-3-kinase; SOCS, suppressor of cytokine signaling; STAT,
signal transducer and activator of transcription; Tg, transgenic.T
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conserved motif referred to as the SOCS box (10). SOCS3
has been characterized as a protein related to CIS1 and
SOCS1 and the expression is transiently induced in a vari-
ety of immune and inflammatory situations by a wide vari-
ety of cytokines, including IFN-
 
 
 
, IL-2, IL-3, IL-6, and
IL-10 (7, 9, 11). In vitro studies have proposed roles for
SOCS3 in growth hormone function (12), IL-2–dependent
T cell proliferation (13), leptin (14), IL-10 (15), and IL-11
(16) signaling. Both SOCS1 and SOCS3 inhibit Janus ki-
nase (JAK) tyrosine kinase activity. SOCS1 directly binds
to the activation loop of JAKs through the SH2 domain
whereas SOCS3 binds to the cytokine receptors. These
two molecules contain a similar kinase inhibitory region
(KIR) at the NH
 
2 
 
terminus that is essential for JAK inhibi-
tion (17, 18). We proposed that KIR interacts with the
region close to the catalytic groove of the JAK2 kinase do-
main, thereby preventing the access of substrates to the cat-
alytic pocket. SOCS3 has been shown to bind to Y757 of
gp130 as well as to Y401 of the erythropoietin receptor,
which are the same binding sites for SHP-2 (19, 20, 21).
Disruption of the SOCS3 gene was shown to result in an
embryonic lethality associated with erythrocytosis (22) and
defects in the placenta (23). Major expression of SOCS3
mRNA has been found in the spleen and thymus, suggest-
ing the importance of SOCS3 in T cell function. T cell
populations that reconstituted in JAK-deficient mice with
fetal liver and the reconstituted T cells were not grossly ab-
normal in T cell development and responsiveness against
cytokine stimulation (22). However, the alternative func-
tion of SOCS3 in the T cell activation process still remains
undetermined. Thus, we studied a role of SOCS3 in T cell
receptor complex–related signaling.
The tyrosine phosphorylation of CD28 regulates the
binding of the lipid/serine kinase, phosphatidylinositol-3-
kinase (PI3-K), and the adaptor protein, growth factor re-
ceptor–bound protein (Grb2), to the cytoplasmic region of
CD28 (24–28). PI3-K is a heterodimer composed of a
dimer of a p85 regulatory subunit and a p110 catalytic sub-
unit. Phosphorylation of CD28 on tyrosine residue 189,
present in a YMNM motif, has been shown to provide a
binding site for the SH2 domain of the p85 regulatory sub-
unit (24). The binding of PI3-K is thought to be crucial for
CD28-mediated IL-2 production. CIS1 and SOCS3 have a
similarity to the PI3-K in the SH2 domain sequence (18).
Therefore, we speculate that SOCS3 plays an alternative
role as a negative regulator for CD28 costimulation. We
have consistently demonstrated that the IL-2 production
ability induced by CD28 costimulation was tightly corre-
lated with the expression level of SOCS3. This inhibitory
mechanism seems to be distinct from that seen for cytokine
signaling. We further studied the mechanisms regulating
the alternative inhibitory functions of SOCS3 for CD28-
mediated signaling.
 
Materials and Methods
 
Mice.
 
The myc-tagged SOCS3 transgenic (Tg) mice under
the control of the lck proximal promoter and the intronic en-
 
hancer from the Ig heavy chain locus (E
 
 
 
) promoter were gener-
ated and backcrossed into C57BL/6 mice. Heterozygous SOCS3
mice were obtained from Jim N. Ihle (St. Jude Children’s Re-
search Hospital, Memphis, TN). DO11.10 Tg mice and IL-4R–
deficient mice on BALB/c background were provided by Ken-
neth Murphy (Washington University, St. Louis, MO) and Frank
Brombacher (University of Cape Town, Cape Town, South Af-
rica). DO11.10 Tg mice and IL-4R–deficient mice were addi-
tionally backcrossed into BALB/c mice for 
 
 
 
10 generations.
 
Proliferative Responses and Preparation of CD4
 
  
 
T Cells.
 
Whole
spleen cells were stimulated with various concentrations of Con
A for 36 h and pulse labeled with 1 mCi of [
 
3
 
H]thymidine for an
additional 8 h. The proliferative responses were measured as
[
 
3
 
H]thymidine incorporation. The enriched CD4
 
  
 
T cells were
prepared from spleen cells by incubation with anti-CD8 mAb (3–
155) followed by incubation with anti–mouse Ig–coated plates to
eliminate B and CD8
 
  
 
T cells.
 
Measurement of IL-2 Concentration by ELISA.
 
The enriched
CD4
 
  
 
T cells were stimulated with plate-bound anti-TCR mAb
(H57-597) in the presence or absence of anti-CD28 mAb (PV-1;
reference 29) for 24 h. The culture supernatants were harvested
and cytokine concentration in the supernatant was measured as
previously described (30). In brief, the supernatants were applied
on the plastic plate coated with anti–IL-2 mAb (JES6-1A12). Af-
ter washing, the plate was probed with biotin-conjugated anti–
IL-2 mAb (JES6-5H4) and horseradish peroxidase–conjugated
streptavidin (Zymed Laboratories) and developed with 2,2
 
 
 
-
azino-bis (3-ethylbenzthiazoline-6-sulfonic acid; Kirkegaard &
Perry Laboratories). The 405-nm absorbance was measured by
spectrophotometer (Bio-Rad Laboratories).
 
Nuclear Extracts and Electrophoretic Mobility Shift Assay.
 
Ex-
tractions of nuclear proteins and electrophoretic mobility shift as-
says were performed as previously described (31). The splenic T
cells were cultured with TCR or TCR/CD28 for 36 h. After
washing with PBS, hypotonic buffer was added to the cell pellet
and incubated on ice for 10 min. The cell membranes were dis-
rupted with 0.15% NP-40. The nuclei were centrifuged at 2,000
rpm for 10 min and the pellets were resuspended in extraction
buffer containing 0.3 M (NH
 
4
 
)
 
2
 
SO
 
4
 
. After incubation at 4
 
 
 
C for
30 min, the nuclear proteins were centrifuged at 100,000 rpm for
10 min and precipitated with 1.5 M (NH
 
4
 
)
 
2
 
SO
 
4
 
. The nuclear
proteins were incubated with 10
 
4 
 
cpm end-labeled oligonucle-
otide probe for 30 min at room temperature in binding buffer.
The samples were loaded on a 4% polyacrylamide gel and run in
low ionic strength buffer. The sequences of oligonucleotide
probe for the nuclear factor (NF)-
 
 
 
B is AGTTGAGGG-
GACTTTCCCAGGC.
 
Northern Hybridization.
 
Total RNA was isolated by the TRI-
zol reagent (GIBCO BRL) and separated on 1.0% agarose gels
containing 2.4% formaldehyde. RNA was transferred to nylon
membranes and then the membranes were hybridized with
digoxigenin-labeled riboprobes and visualized by alkaline phos-
phatase–leveled anti-digoxigenin antibody (Roche Diagnostic).
 
Reagent and Immunoblot Analysis.
 
Total cell extracts were pre-
pared from tissue homogenized in 50 mM Tris-HCl, pH 8.0,
0.5% NP-40, 1 mM EDTA, 150 mM NaCl, 10% glycerol, 1 mM
sodium vanadate, 50 mM sodium fluoride, 10 mM sodium pyro-
phosphate, and 1 mM PMSF with a protease inhibitor cocktail
(Sigma-Aldrich). The samples were resolved on SDS-PAGE and
the proteins were detected by immunoblotting. Antibodies
against murine extracellular signal–regulated kinase (ERK)2,
myc, and CD28 were purchased from Santa Cruz Biotechnology,
Inc. Tyrosine-phosphorylated ERKs were detected by anti-T
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pERK antibodies (Promega). Antibodies against SOCS3 were
raised in rabbit using a synthetic peptide.
 
Binding of SOCS3 to Glutathione S-transferase (GST) Protein In
Vitro.
 
GST-CD28 construct was provided by Takashi Saito
(Chiba University, Chiba, Japan). GST-CD28 in pGEX-4T-1
(Amersham Biosciences) were transformed into 
 
Escherichia coli
 
BL21(DE3) strain or TKB1 strain, which is a tyrosine kinase de-
rivative of the BL21(DE3) (Stratagene). GST fusion protein was
induced by 0.4 mM isopropyl-
 
 
 
-D-thiogalactopyranoside for 2 h
and immobilized on glutathione-Sepharose 4B (Amersham Bio-
sciences). Myc-tagged SOCS3 was transfected into HEK293 cells
and the transfected cells were extracted after 24 h of transfection.
Cell extracts were incubated with 20 
 
 
 
l (50% vol/vol) of GST-
Sepharose for 1 h at 4
 
 
 
C. After washing twice with lysis buffer,
the precipitates were analyzed by immunoblotting.
 
Preparation of Th1 and Th2 Cells.
 
DO11.10 Tg spleen cells
were incubated with anti-CD8 mAb (3–155) at 4
 
 
 
C and the cells
were incubated on plate-coated anti–mouse Ig to eliminate B and
CD8
 
  
 
T cells to isolate CD4
 
  
 
T cells. The CD4
 
  
 
T cells were
stimulated with OVA antigenic peptide (residues 323–339;
ISQAVHAAHA EINEAGR; BEX Corporation) in the presence
of irradiated BALB/c APCs. The induction of Th1 and Th2 cells
was controlled by the addition of either 10 unit/ml mouse IL-12
plus anti–IL-4 mAb or 100 unit/ml mouse IL-4 plus anti–IL-12
mAb, respectively.
 
Transfection and Luciferase Assay.
 
5 
 
  
 
10
 
6 
 
Jurkat cells were
cotransfected with 5 
 
 
 
g IL-2 reporter construct (31), 2 
 
 
 
g
pSV2
 
  
 
placental alkaline phosphatase, 5 
 
 
 
g pcDNA3 mouse
CD28, and 5 
 
 
 
g pcDNA3 myc SOCS3 constructs by electropo-
ration (32). The pSV2
 
  
 
phosphatase plasmid was used for nor-
malizing the transfection efficiency. The transfected cells were
stimulated for 12 h with 10 
 
 
 
g/ml anti–human CD3 mAb
(OKT3), a combination of anti-CD3 and anti–mouse CD28
(PV-1) mAbs, or a combination of 50 ng/ml PMA plus 1 
 
 
 
M
ionomycin. After 12 h, the cells were harvested and divided into
two groups. 20% of the cells were then used for the measurement
of alkaline phosphatase activity. The rest of the cells were used for
the measurement of the luciferase activity. The emitted luciferase
light in substrate solution (Promega) was measured with a lumi-
nometer (Analytical Luminescience Laboratory).
 
Results
 
SOCS3 Negatively Regulated CD28-mediated IL-2 Produc-
tion.
 
Here, we attempted to study the role of SOCS3 in
TCR-related responses using Tg strains of mice expressing
WT SOCS3 driven by lck-E
 
  
 
promoter. All four Tg lines
were indistinguishable from control littermates in body
size, weight, and behavior. Thymocytes and splenic T cells
from Tg mice exhibited similar expression profiles of sev-
eral T cell markers (CD4, CD8, TCR
 
 
 
, CD28, CD25,
CD69, CD44, and CD62L) compared with normal litter-
mate mice, although the number of thymocytes and splenic
T cells was slightly reduced in Tg mice (unpublished data).
Protein expression from the myc-tagged transgene was
 
 
 
5–10 times higher than that of endogenous SOCS3 (un-
published data).
To study the proliferative responses of peripheral T cells,
splenocytes were stimulated with T cell mitogen, Con A.
As shown in Fig. 1 A, spleen cells from SOCS3 Tg mice
showed a marked reduction in the proliferative responses
to approximately half that seen in littermate mice. This re-
sult raised the possibility that SOCS3 was implicated in the
negative regulation of TCR-mediated signaling. Thus, IL-2
production in CD4
 
  
 
naive T cells was measured at various
time points after stimulation with anti-TCR mAb in the
presence or absence of CD28 costimulation. In control
mice, the anti-TCR mAb-activated T cells expressed very
low but detectable amounts of IL-2 and in conjunction
with CD28 costimulation, IL-2 production was very
strongly enhanced 
 
 
 
250 times. Interestingly, SOCS3 Tg
T cells consistently exhibited less augmentation in CD28-
mediated IL-2 production although the TCR-mediated
IL-2 production was comparable to that of control litter-
mate mice (Fig. 1 B). The augmentation rate in SOCS3
Tg was consistently less than half of that in the control
mice (Fig. 1 B). A similar reduction was observed in the
Tg mice expressing the mutant of SOCS3, F25A, which
contains a point mutation in KIR that is a critical for the
inhibition of cytokine signaling including IL-2 (unpub-
lished data). F25A SOCS3 mutant inhibited CD28-medi-
ated augmentation in IL-2 production (Fig. 1, B and C).
This SOCS3-mediated inhibition could not be attributed
to the alteration of CD28 expression levels because T cells
from SOCS3 Tg exhibited comparable CD28 expression
to control T cells (unpublished data). Therefore, we specu-
late that SOCS3 has an alternative role as a negative regu-
lator of the CD28 costimulation signal and machinery of
the negative regulation seems to be distinctive from that of
the cytokine signaling.
 
Forced SOCS3 Expression Inhibits CD28-mediated NF-
 
 
 
B
Activation.
 
A recent report addressed the possibility that
SOCS3 inhibits TCR signaling in the human Jurkat cell
line via the binding to the active form of calcineurin (33).
However, the alteration of SOCS3 expression did not af-
fect the IL-2 production in response to TCR alone in
SOCS3 Tg mice. Thus, we further explored the relevance
of SOCS3 in TCR-mediated T cell responses and exam-
ined the cell surface expression of the T cell activation
markers, CD25 and CD69. The up-regulation of these two
molecules in activated T cells is mainly controlled by
TCR-mediated signals. As shown in littermate control
splenic T cells (Fig. 2 A), TCR stimulation fully activated
CD25 and CD69 expression within 24 h, but CD28 signal
did not show costimulation effect in CD25 and CD69 ex-
pression. T cells from SOCS3 Tg mice also exhibited full
activation of CD25 and CD69 expression, supporting our
speculation that SOCS3 has no inhibitory effect on the sig-
naling events mediated by TCR activation.
CD28 can activate several signaling events that integrate
those governed by TCR cross-linking. Thus, CD28 in-
creases TCR-mediated ERK activation by Rap-1 inhibi-
tion (34). Next, we explored SOCS3 function on the ERK
activation by TCR and CD28 stimulation. In littermate T
cells, ERK1/2 phosphorylation was induced with TCR
cross-linking and CD28 clearly enhanced ERK1/2 activa-
tion. However, unlike littermate T cells, SOCS3 Tg CD4
 
 
 
T cells showed ERK1/2 phosphorylation without the
stimulation. The ERK1/2 phosphorylation was marginallyT
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enhanced by TCR cross-linking but not by CD28 costim-
ulation (Fig. 2 B). These results indicated that constitutive
expression of SOCS3 altered the phosphorylation status of
ERK pathway in CD4
 
  
 
T cells, perhaps because SOCS3
alone can partially enhance basal ERK activation levels
(35), but this alteration might not influence the TCR-
induced IL-2 production and expression of activation
markers. Even under these circumstances, SOCS3 might
have retained the inhibitory function for the CD28-medi-
ated enhancement of ERK1/2 phosphorylation.
Maximum activation of the IL-2 gene is accomplished
by the combination of TCR and CD28 costimulation.
These two signals lead to the synergistic activation of NH
 
2
 
-
terminal kinase and NF-
 
 
 
B. The activated NF-
 
 
 
B is
known to bind the CD28RE contained in the IL-2 pro-
moter, leading to a marked up-regulation in IL-2 transcrip-
tion. To study a role of SOCS3 in CD28-mediated NF-
 
 
 
B
activation, CD4
 
  
 
T cells were stimulated with TCR cross-
linking in the presence or absence of anti-CD28 mAb. The
translocation of NF-
 
 
 
B into the nuclei was assessed by the
binding to the putative sequence for NF-
 
 
 
B. As shown in
Fig. 2 C, TCR cross-linking induced weak NF-
 
 
 
B nuclear
translocation and CD28 signal was required for full activa-
tion of NF-
 
 
 
B in control mice. The T cells from SOCS3
Tg mice exhibited less augmentation in NF-
 
 
 
B nuclear
translocation by CD28 costimulation, indicating that con-
sistent with the IL-2 production, SOCS3 inhibited NF-
 
 
 
B
activation induced by CD28 costimulation.
 
Induction of SOCS3 Expression during Primary T Cell Acti-
vation.
 
Forced expression of SOCS3 inhibits the CD28
costimulation-mediated IL-2 production in early T cell acti-
vation, but it was still unclear whether a significant amount
of SOCS3 are expressed during early T cell activation.
Thus, we examined the expression of CIS-1, SOCS1, and
Figure 1. Impairment of Con A–induced T cell activa-
tion and CD28-induced IL-2 production in T cells from
SOCS3 Tg mice. (A) Impairment of Con A–induced T
cell activation in SOCS3 Tg mice. Whole spleen cells from
control littermate (LM) or SOCS3 Tg mice were stimu-
lated with various concentration of Con A for 36 h. Prolif-
erative response was measured by [3H]thymidine incorpo-
ration in the last 8 h. (B) IL-2 production in T cells from
control LM, WT SOCS3, and KIR mutant SOCS3 F25A
Tg mice. The CD4  T cells from control LM, SOCS3 Tg,
and F25A Tg mice were stimulated with anti-TCR mAb
or a combination of anti-TCR and anti-CD28 mAb. The
culture supernatants were harvested at various time points
and the amount of IL-2 was measured by ELISA. (C) IL-2
production at 48 h in the activated T cells from SOCS3
and F25A Tg. The mean   SD shown was obtained from
five mice. *, P   0.05 versus control littermates.T
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SOCS3 in the primary stimulation of naive T cells. CD4
 
  
 
T
cells from BALB/c mice were activated with either TCR or
TCR plus CD28 mAbs and mRNA expression was assessed
by Northern blot analysis. The CIS-1 and SOCS1 expres-
sions were also induced by a combination of TCR and
CD28 costimulation and the maximum expression level was
found within 48 h (Fig. 3). The expression profile of
SOCS3 mRNA differed from that of CIS-1 and SOCS1
because resting CD4
 
  
 
T cells expressed a significant level of
SOCS3 and the expression was rapidly decreased after TCR
stimulation. The expression recovered after 48 h and
reached the maximum level at 72 h when T cells were co-
stimulated with anti-CD28 mAb (Fig. 3). Therefore, a sig-
nificant amount of SOCS3 were expressed in the primary
IL-2 production process and CD28 costimulation may play
a role to rapidly enhance the expression level of SOCS3.
Figure 2. Effects of constitutive expression of SOCS3 on TCR and CD28-mediated signaling events. (A) Effects of constitutive expression of SOCS3 on
CD25 and CD69 expression. The CD4  T cells from littermate (LM) and SOCS3 Tg mice were stimulated with plate-bound anti-TCR in the presence or
absence of anti-CD28 for 48 h and then the expression of CD25 and CD69 were analyzed by flow cytometric analysis. (B) Effects of constitutive expression
of SOCS3 on ERK activation. Naive splenic T cells were incubated with anti-TCR in the presence or absence of anti-CD28 mAb (1 and 3  g/ml). Cell
extracts were resolved by SDS-PAGE and immunoblotted with anti-pERK (top) or anti-ERK2 (bottom) antibody. (C) Effects of constitutive expression of
SOCS3 on CD28-mediated NF- B activation. Electophoretic mobility shift assays were performed with nuclear extracts from T cells unstimulated (lane 1),
stimulated with anti-TCR (lanes 2 and 4), and anti-TCR plus anti-CD28 mAb (lanes 3 and 5). Arrow indicates the binding of NF- B.
Figure 3. Induction of SOCS3 expression during early
T cell activation. CD4  T cells from BALB/c mice were
activated with either TCR or TCR plus CD28 mAbs and
mRNA expressions of CIS-1, SOCS1, SOCS3, and
G3PDH were assessed by Northern blot analysis at various
time points after stimulation.T
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Increased CD28-mediated IL-2 Production in SOCS3 Heter-
ologous Mice.
 
In forced expression studies using Tg ap-
proaches it is difficult to fully interpret the physiological
relevance of SOCS3. Thus, we next assess the CD28-
mediated IL-2 production in SOCS3 heterologous mice.
Naive CD4
 
  
 
T cells did not exhibit detectable protein ex-
pression of endogenous SOCS3 and the protein expression
only appeared after stimulation with anti-TCR and CD28
mAb. The protein expression levels in activated T cells
from SOCS3
 
    
 
mice were 5–10 times lower than those in
SOCS3
 
    
 
T cells (Fig. 4 A), but the reduction did not al-
ter T cell development based on cell surface markers (un-
published data). When T cells were stimulated with anti-
TCR cross-linking, T cells from SOCS3 heterologous
mice produced equivalent amount of IL-2 compared with
that of SOCS3
 
    
 
T cells (Fig. 4 B). In contrast, the CD28-
mediated enhancement of IL-2 production was markedly
augmented in T cells from SOCS3
 
    
 
mice (Fig. 4 B). The
IL-2 production levels in SOCS3
 
    
 
T cells were consis-
tently twofold higher than those of SOCS3
 
    
 
T cells.
These results clearly indicated that the decreased expression
level of SOCS3 enhanced CD28-mediated IL-2 produc-
tion ability in primary T cell activation.
 
SOCS3 Inhibited CD28-mediated IL-2 Promoter Activa-
tion.
 
We further examined the molecular basis of the neg-
ative regulation of CD28 costimulation by SOCS3. To
minimize the effect of endogenous CD28 molecules,
mouse CD28 molecule was transfected into Jurkat cells.
WT or mutated SOCS3 (R71E and F25A) was further
cotransfected with the IL-2 promoter luciferase reporter
gene, which contains CD28RE sequence. R71E is a substi-
tution mutant at the SH2 domain whereas F25A contains a
point mutation at the KIR. Both cannot inhibit IL-2–
induced STAT5 activation (18 and unpublished data). The
Figure 4. (A) SOCS3 protein expression in activated T
cells from SOCS3    and SOCS3    mice. T cells from
three SOCS3    and SOCS3    mice with C57BL/6 back-
ground was stimulated with anti-TCR and anti-CD28
mAb for 48 h. SOCS3 and STAT6 protein expression was
analyzed by Western blotting using specific antibody.
STAT6 expression is represented as an internal control.
The mean   SD of optimal densities was obtained from
three independent experiments. *, P    0.05 versus
SOCS3    mice. (B) T cells from three SOCS3    and
SOCS3    mice with C57BL/6 background was stimulated
with anti-TCR in the presence or absence of anti-CD28
mAb. Three different concentration of the culture superna-
tant of anti-CD28 mAb (1–10%) were added. The culture
supernatants of the stimulated T cells were harvested at
48 h and IL-2 concentration was measured by ELISA. The
mean   SD shown was obtained from three mice.T
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Jurkat cells expressing mouse CD28 were stimulated with
either anti–human CD3 plus anti–mouse CD28 mAb,
PMA plus anti–mouse CD28 mAb, or PMA plus ionomy-
cin. The overexpression of WT and F25A mutant inhibited
CD28-mediated IL-2 promoter activation (Fig. 5, left and
middle) but did not affect the CD28-independent IL-2
promoter activation using a combination of PMA and ion-
omycin (Fig. 5, right). On the other hand, the mutation at
SH2 region (R71E) exhibited no inhibition for the IL-2
promoter (Fig. 5, middle). These results suggested that the
SH2 domain is responsible for the inhibition of CD28-
mediated IL-2 promoter activation and that SOCS3 possi-
bly acts on CD28 costimulation through its SH2 domain.
Binding of SOCS3 to Tyrosine-phosphorylated CD28
Through Its SH2 Domain. Previous reports have clearly
demonstrated that the inhibitory function of SOCS3 is
based on the interaction with the tyrosine-phosphorylated
JAK and/or the cytokine receptor (13, 18). Thus, we ex-
amined whether tyrosine phosphorylation of CD28 is criti-
cal for the interaction between CD28 and SOCS3. GST or
GST fused to CD28 cytoplasmic domain (GST-CD28)
were bacterially tyrosine phosphorylated and incubated
with the cell extract from 293 cells expressing myc-tagged
SOCS3. GST-CD28 proteins were precipitated by glu-
tathione-Sepharose beads and coprecipitation of SOCS3
was assessed by blotting with anti-myc mAb. As shown in
Fig. 6 A, SOCS3 specifically coprecipitated with the ty-
rosine-phosphorylated CD28 but not unphosphorylated
CD28. To further determine the binding motif on SOCS3,
CD28 was coexpressed in 293 cells with either WT or mu-
tant SOCS3 and the association of SOCS3 was examined
by precipitation with anti-CD28 mAb. WT and F25A
were coprecipitated with the tyrosine-phosphorylated
CD28 whereas R71E, an SH2 mutant, was not precipitated
with CD28 (Fig. 6 B). To confirm this association in T
cells from SOCS3 Tg mice, thymocyte extracts were im-
munoprecipitated with anti-CD28 mAb after activation
with anti-TCR and CD28 mAbs. In this experiment,
F25A Tg mice were used to eliminate the alternative effect
of inhibitory function for the cytokine signal. Consistently,
T cells from F25A Tg mice showed an inducible associa-
tion with CD28 when T cells were stimulated with anti-
TCR plus CD28 mAb (Fig. 6 C), demonstrating that SH2
domain but not KIR on SOCS3 is critical for the associa-
tion with the tyrosine-phosphorylated CD28.
Redundant Binding of SOCS3 to Tyrosine-phosphorylated
CD28. It has been well documented that the tyrosine
residue within the YMNM motif of the cytoplasmic region
of CD28 is a target site for PI3-K and Grb2, which trans-
duce signals downstream (24–28). We notice that the
SOCS3 SH2 domain shows a sequence similarity to the
PI3-K SH2 domain (unpublished data). Thus, it is reason-
able to speculate that the expressed SOCS3 specifically
binds to the YMNM motif on CD28 and inhibits the asso-
ciation of PI3-K to the phosphorylated CD28. To study
this possibility, we attempt to compare the association of
PI3-K to the phosphorylated CD28 between T cells from
the littermate and Tg mice. Thymocytes from F25A Tg
mice clearly revealed the reduction of PI3-K association to
CD28 when cells were stimulated with the combination of
anti-TCR and CD28 mAb (Fig. 6 C), suggesting that the
forced expression of SOCS3 inhibited the association of
PI3-K with CD28 in thymocytes. However, this inhibition
was only observed in Tg-derived thymocytes but not in
spleen T cells because the expression level of transgene in
thymocytes was 10 times higher than that in spleen T cells
(unpublished data).
We further studied whether SOCS3 specifically recog-
nize the tyrosine residue (Y189) in the YMNM motif on
CD28. Thus, a series of mutant CD28 were generated by
either substitution at each tyrosine residue or deletion and
were expressed in 293 cells with SOCS3 (Fig. 6 D). The
tyrosine residue at 189 has been shown to be critical for the
association with PI3-K and Grb family molecules (24). In-
Figure 5. Inhibition of CD28-
mediated IL-2 promoter activa-
tion by SOCS3. The IL-2 pro-
moter (10  g) and SOCS3 (5  g)
constructs were cotransfected into
Jurkat cells and then cultured for
24 h. After transfection, cells were
stimulated with anti-CD3 plus
anti-CD28 mAb (top left), PMA
plus anti-CD28 mAb (top mid-
dle), or PMA plus ionomycin (top
right). WT, KIR mutant, and
SH2 mutant of SOCS3 were rep-
resented as WT, F25A, and R71E,
respectively. Protein expression of
transfected WT and mutant
SOCS3 was indicated by Western
blotting with anti-Myc mAb (bot-
tom columns). The data represents
mean value of fold induction
against the relative light unit of
unstimulated Jurkat cells. The
mean     SD was obtained from
three independent experiments.T
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deed, the substitution mutant, Y189F, abrogated binding to
both PI3K or Grb2 and CD28-induced signaling was as-
sessed by IL-2 production (unpublished data). However,
when SOCS3 was transfected with 293 cells with either
WT or Y189F CD28, SOCS3 was immunoprecipitated
with WT CD28 as well as YF189 mutant (Fig. 6 D, lane
5). Unexpectedly, the association between CD28 and
SOCS3 was not canceled in either of four substitution mu-
tants (YF189, 204, 207, and 216) as well as the deletion of
the YMNM motif of CD28 (Fig. 6 D, right). These result
indicated that the association between CD28 and SOCS3
was dependent on the SH2 domain of SOCS3 and the ty-
rosine phosphorylation of CD28, however, multiple tyro-
sine phosphorylation sites of CD28 could interact with
SOCS3. Nevertheless, the binding of SOCS3 protein to
CD28 inhibited the association of PI3-K to tyrosine-phos-
phorylated CD28
As shown in Fig. 6 C, SOCS3 inhibited the association
of PI3-K with CD28 when high amounts of SOCS3 pro-
tein were expressed. However, it is very difficult to con-
clude that the inhibition of the PI3-K association con-
tributed to the SOCS3-mediated inhibition of CD28
costimulation in physiological conditions. Therefore, we
next compared the association of PI3-K with the phos-
phorylated CD28 between DO11.10-derived Th1 and
Th2 cells on the basis of our previous finding that SOCS3
protein was exclusively expressed in Th2 but not Th1 cells
(Fig. 7 A; references 36 and 37). PI3-K was coprecipitated
with CD28 in Th1 cells after stimulation with anti-CD28
mAb. However, Th2 cells show a weak association be-
tween CD28 and PI3K even though the expression levels
of CD28 and PI3K were indistinguishable between Th1
and Th2 cells (Fig. 7 A). These data suggest that inhibition
of the association between CD28 and PI3-K by SOCS3
protein may occur at physiological levels. Furthermore, the
CD28 dependency in cytokine production was different
between Th1 and Th2 cells (Fig. 7 B). Th1 cytokines, such
as IL-2 and IFN- , showed a greater fold induction medi-
ated by CD28 costimulation than those of Th2 cytokines,
IL-4 and IL-5 (Fig. 7 B). These results indicated that com-
pared with Th1 cells, the effect of CD28 costimulation on
cytokine production is decreased in Th2 cells that exclu-
sively express SOCS3 protein.
Induction of SOCS3 Expression Reduced CD28-mediated
IL-2 Production at Primary T Cell Activation. We have re-
cently reported that SOCS3 was strongly and specifically
expressed in the presence of IL-4 in naive T cells (unpub-
lished data). Thus, we compared primary IL-2 production
controlled by CD28 costimulation between the mice in the
presence and absence of IL-4 receptor signaling. T cells
Figure 6. Binding SOCS3 to the phosphorylated CD28 molecule through the SH2 domain. (A) Binding specificity of SOCS3. Myc-SOCS3 was tran-
siently expressed in HEK293 cells. The cell lysate was mixed with either GST-CD28 or GST-CTLA4 and the bound myc-SOCS3 was estimated by
immunoblotting with anti-myc. Purified GST protein was detected by Coomassie Brilliant Blue stain. (B) Binding domain on SOCS3 to CD28.
HEK293 cells cotransfected with the CD28 plasmid and either SOCS3, F25A, or R71E expression constructs. After 24 h, 293 cells were incubated with
(lanes 2, 4, and 6) or without (lanes 1, 3, and 5) pervanadate for 5 min. Cell extracts (1 mg) were immunoprecipitated by anti-CD28 antibody and immu-
noblotted with anti-myc or anti-CD28 antibodies. (C) Association of SOCS3 with CD28-reduced PI3-K binding. Thymocytes (108 cells) from littermate
(LM; lanes 1 and 2) and F25A Tg (lanes 3 and 4) mice were stimulated with anti-TCR and anti-CD28 mAb for 2 min (lanes 2 and 4). The cell lysate was
immunoprecipitated with anti-CD28 mAb and the association of PI3-K and SOCS3 was visualized by immunoblotting with either anti–PI3-K or anti-
myc antibody. (D) Redundant association of SOCS3 with CD28. HEK293 cells cotransfected with WT SOCS3 and WT (lanes 1, 2, 3, and 7), YF mu-
tants (lanes 4, 5, 8, 9, 10, and 11), or deletion mutant (lane 12) of CD28. After 24 h, 293 cells were incubated with (lanes 3, 5, and 6–12) or without
(lanes 1, 2, and 4) pervanadate for 5 min. The immunoprecipitates with anti-CD28 antibody were immunoblotted with anti-myc or anti-CD28 antibodies.T
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from DO11.10 and DO11.10 IL-4R    mice on BALB/c
background were stimulated with OVA peptide in the
presence of APCs and expression levels of IL-2 and SOCS3
were assessed after 48 h. The induction of SOCS3 expres-
sion was minimized in DO11.10 IL-4R    T cells (Fig. 8
A). However, DO11.10 IL-4R    T cells stimulated with
BALB/c APCs produced twice as much IL-2 compared
with that of DO11.10 T cells from IL-4R WT mice (Fig. 8
A). These data indicate that the effect of SOCS3 on IL-2
production was not only observed in anti-CD3 and CD28
antibody stimulation but also in the response to natural an-
tigen and costimulators.
A similar relationship was observed between BALB/c
and B10.D2 strains of mice that have a distinct ability in
IL-4 production at primary T cell activation (38, 39). Na-
ive CD4  T cells from BALB/c mice secreted 10 times
more IL-4 than that of B10.D2 mice (Fig. 8 B). Consistent
with the differential IL-4 production, the activated BALB/c
T cells but not B10.D2 T cells showed clear SOCS3 ex-
pression. BALB/c T cells in which SOCS3 expression was
induced by IL-4 had half the IL-2 production observed in
B10.D2 T cells in response to CD3 and CD28 (Fig. 8 B).
These results indicated that the IL-4–induced SOCS3 ex-
pression during primary T cell activation inhibited the IL-2
production after CD28 costimulation.
Discussion
Members of the SOCS family were discovered as nega-
tive regulators of cytokine signaling capable of inhibiting
the JAK-STAT pathway (8–10, 40). Much evidence has
indicated that SOCS3 can bind JAK tyrosine kinases and
inhibit the JAK-STAT signaling activated by various cyto-
kines including leukemia inhibitory factor, IL-2, IL-6,
erythropoietin, and prolactin (7). This study describes that
when SOCS3 is expressed in T cells, CD28-mediated IL-2
production is inhibited. The inhibitory action was distinct
from that for cytokine signaling in which both the KIR
and SH2 domain were indispensable whereas the SH2 do-
main was sufficient for the inhibition of CD28 costimula-
tion. The expressed SOCS3 in early T cell activation may
have an alternative role in prohibiting excessive T cell acti-
vation mediated by CD28 costimulation.
The sequence of SH2 domain on SOCS3 showed simi-
larity to the PI3-K SH2 domain, suggesting the possibility
that SOCS3 may share similar binding specificity with
PI3-K. Therefore, we speculated a role of SOCS3 in the
CD28 signaling pathway and thus studied CD28-mediated
IL-2 production using Tg mice constitutively expressing
SOCS3 protein and SOCS3 /  mice. Because SOCS3 ex-
pression levels were regulated by IL-4, we studied the rela-
tionship between SOCS3 expression and CD28-mediated
IL-2 production in the conditions in which either the IL-4
signal or IL-4 was restricted (Fig. 8). The reduction of
CD28-mediated IL-2 production was consistently ob-
served along with the increased expression level of SOCS3
in all the systems examined in this study. These results
clearly indicated that SOCS3 has an alternative function as
a negative regulator for the CD28-mediated IL-2 produc-
tion in primary T cell activation. SOCS3 mRNA was con-
stitutively expressed in naive CD4 T cells and the expres-
sion was rapidly down-regulated by TCR cross-linking.
However, the presence of CD28 costimulation could
overcome SOCS3 expression within the first 48 h, sug-
gesting that SOCS3 induced during early T cell activation
may account for negatively controlling the excessive pro-
gression of CD28-mediated IL-2 production.
SOCS3 not only play a role during primary T cell acti-
vation but may also be important in committed Th cells. It
has been recently reported that Th2 cells exclusively ex-
pressed SOCS3 protein (Fig. 6; references 36 and 37). The
differential expression of SOCS3 strongly correlated with
the dependency for CD28 costimulation during cytokine
production from DO11.10 Tg-derived Th1 and Th2 cells.
Th1 cytokines, such as IL-2 and IFN- , showed prominent
Figure 7. Expression of SOCS3 in Th2 cells impaired the association
of PI3-K with CD28. (A) DO11.10 CD4  T cells with BALB/c back-
ground were stimulated with OVA peptide under either Th1 or Th2 po-
larizing conditions. Protein expression of PI3-K, CD28, SOCS3, and
STAT6 was analyzed 7 d after OVA stimulation (left). These Th1 and
Th2 cells were stimulated with soluble anti-CD28 mAb (20  g/ml) for
10 min and the cell extracts were precipitated with anti-CD28 mAb. The
association of PI3-K was assessed by Western blot analysis with anti–PI3-K
antibody (right). The same experiment was performed three times with
the same result. (B) DO11.10-derived Th1 and Th2 cells were stimulated
with immobilized anti-TCR mAb (10  g/ml) in the presence or absence
of anti-CD28 mAb (10% culture supernatant) and cytokine productions
were measured. CD28-mediated cytokine productions are represented as
fold induction versus the anti-TCR mAb-mediated cytokine production.T
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CD28-mediated enhancement whereas a large amount of
the Th2 cytokines, IL-4 and IL-5, were capable of secret-
ing with TCR cross-linking, and the dependency for
CD28 costimulation was less than that of the Th1 cyto-
kines (Fig. 7 B). These results were consistent with the
observation that the presence of SOCS3 attenuated CD28-
mediated IL-2 production in early T cell activation. Inter-
estingly, Th2 cells exhibited very low association of PI3-K
with CD28 when cells were activated with anti-CD28
mAb. Despite this, Th1 cells showed a clear association be-
tween PI3-K and CD28 (Fig. 7 A), suggesting that SOCS3
inhibits CD28-dependent signaling through the reduction
of the association of PI3-K with CD28.
Our biochemical characterization and in vitro muta-
tional analysis have demonstrated that the mechanism of an
SOCS3 inhibition of the CD28 costimulation is distinct
from the inhibition of cytokine signaling as in the latter in-
teractions at both the SH2 domain and KIR on SOCS3 are
required. Our data show that the SH2 domain is sufficient
with SOCS3 interaction with the phosphorylated CD28
(Fig. 6). Previous reports have provided substantial evi-
dence that the tyrosine residues within the CD28 YMNM
motif are critical for binding Grb2 and the PI3-K p85 sub-
unit by which the CD28-mediated signal is transduced
downstream (24–28). Therefore, we speculated that the
YMNM motif on the cytoplasmic region of CD28 would
be a target site for SOCS3 binding. The low association of
PI3-K with CD28 that we observed in SOCS3 Tg-derived
thymocytes (Fig. 6 C) and Th2 cells (Fig. 7 A) supports our
speculation. However, SOCS3 can redundantly bind to all
four phosphorylated tyrosine residues on CD28 (Fig. 6 D),
indicating that the YMNM motif is not a specific target of
SOCS3. Therefore, although the reciprocal interaction of
CD28 with PI3-K and SOCS3 partly involves the inhibi-
tory function for CD28-mediated IL-2 production, it re-
mains a possibility that a different mechanism was responsi-
ble for the inhibition of CD28 costimulation by SOCS3.
Additional investigation is necessary to elucidate the inhib-
itory mechanisms of CD28-mediated responses by SOCS3.
The activation and subsequent proliferation of peripheral
T cells requires the engagement of the TCR. The mem-
bers of the SOCS family have been well documented as
negative regulators of cytokine signaling via inhibition of
the JAK-STAT pathway. However, there has been little
evidence that they have broader functions across T cell and
cytokine receptor signaling pathways. A recent report has
described that CIS-1 play a role in enhancing mitogen-
activated protein kinase activation initiated by TCR stimu-
lation. The CIS-1–increased MAP kinase was elucidated
with a direct interaction of CIS-1 and protein kinase C 
(41). In biochemical characterization, SOCS3 has been
shown to associate with T cell–specific tyrosine kinase
p56lck in in vitro binding assays (8). Recently, it has been
reported that SOCS3 can associate with a catalytic subunit
of calcineurin, resulting in the inhibition of calcineurin-
dependent NF-ATp activation (33). However, either en-
hanced or reduced expression of SOCS3 did not have
marked effects on T cell development nor TCR-mediated
IL-2 production (Fig. 1). Consistently, SOCS3-deficient
mice that the T cells reconstituted in JAK3-deficient mice
with SOCS3-deficient fetal liver cells showed no alteration
in T cell development nor the IL-2–induced proliferative
response (22). T cells from SOCS3 Tg and heterologous
mouse exhibit reciprocal alteration of the CD28-mediated
IL-2 production in primary T cell activation. Similarly, T
cells from CD28-deficient mice impaired in the primary T
Figure 8. IL-4–induced SOCS3
expression negatively regulated
CD28-mediated IL-2 pro-
duction. (A) CD4  T cells were
prepared from DO11.10 or
DO11.10 IL-4R–deficient mice
with BALB/c background and
stimulated with OVA peptide in
the presence of BALB/c APC
and IL-4 for 48 h. SOCS3 and
G3PDH mRNA expression
(bottom) and IL-2 production
(top) were analyzed. The same
experiment was performed three
times with the same result. (B)
CD4   T cells were prepared
from BALB/c and B10.D2
strains of mouse. The cells were
stimulated with anti-TCR and
anti-CD28 mAb in unskewed
condition for 48 h. SOCS3 and
G3PDH mRNA expression and
IL-2 and IL-4 production were
analyzed. The mean    SD in
IL-2 and IL-4 production shown
was obtained from three mice.T
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cell activation mediated by the B7–CD28 interaction but
not T cell development nor TCR-mediated IL-2 produc-
tion (42). Thus, it is reasonable to speculate that a func-
tional target in TCR-related signaling is the CD28-medi-
ated signaling. The rapidly induced SOCS3 during the
early T cell activation may play an important role to nega-
tively regulate the excessive primary IL-2 production in-
duced by CD28 costimulation.
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